Among the study population, 117 patients were identified as being potentially suitable for inclusion in clinical trials, based on FGFR2- and/or HER2-positive status (GC = 45, CRC = 72; FGFR = 56, HER2 = 62 [1 patient was FGFR2- and HER2-positive]). This evidence concerns the gene ERBB2 and gastric cancer.